Navigation Links
Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
Date:9/21/2009

ZURICH, September 21 /PRNewswire/ -- Occlutech AG, the leading European developer of products for septal closure, today announced that, together with its partner in Spain IZASA SA, it defeated a request for an injunction against sales and marketing activities in Spain, launched at the Commercial Court I of Barcelona, Spain by its U.S. competitor AGA Medical.

The request by AGA was based on alleged patent infringement and unfair competition claims related to wrongful assumptions and misleading statements about the outcome of a recent ruling by the patent court in Dusseldorf and about Occlutech.

The Court came to the conclusion that Occlutech's products offered for sale by IZASA do not infringe patent EP0808138 held by AGA in Spain that is Europe's fifth largest market.

Further in October 2008 Occlutech won against AGA Medical in the District Court of The Hague. In December 2008 the Higher Regional appeal Court in Dusseldorf, that has no jurisdiction over sales by Occlutech's partners outside of Germany, decided against Occlutech. In July 2009, however, the Patents Court of the High Court of Justice, London declared that Occlutech's products are not infringing AGA's patent EP 0808138.

Above Court decisions are not final and subject to appeal that are/can be filed by AGA or Occlutech.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.


'/>"/>
SOURCE Occlutech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
2. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
3. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
4. Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
5. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
6. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
7. Aspreva obtains shareholder approval for acquisition by Galenica
8. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
9. DRAXIS Obtains Interim Order for Proposed Arrangement
10. DRAXIS Obtains Final Order for Proposed Arrangement
11. China Medicine Corporation Obtains Australian Patent for rADTZ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: